1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Pipeline Review, H1 2020, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.
Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Dengue Fever - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 11, 26, 13 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 12 and 12 molecules, respectively.
Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Dengue Fever - Overview
- Dengue Fever - Therapeutics Development
- Dengue Fever - Therapeutics Assessment
- Dengue Fever - Companies Involved in Therapeutics Development
- Dengue Fever - Drug Profiles
- Dengue Fever - Dormant Projects
- Dengue Fever - Discontinued Products
- Dengue Fever - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Dengue Fever, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020 (Contd..2), H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Dengue Fever - Pipeline by 60 Degrees Pharmaceuticals LLC, H1 2020
- Dengue Fever - Pipeline by Abhelix LLC, H1 2020
- Dengue Fever - Pipeline by Abivax SA, H1 2020
- Dengue Fever - Pipeline by AbViro LLC, H1 2020
- Dengue Fever - Pipeline by Aluda Pharmaceuticals Inc, H1 2020
- Dengue Fever - Pipeline by Atea Pharmaceuticals Inc, H1 2020
- Dengue Fever - Pipeline by Avida Biotech SL, H1 2020
- Dengue Fever - Pipeline by Biological Mimetics Inc, H1 2020
- Dengue Fever - Pipeline by BioNet- Asia Co Ltd, H1 2020
- Dengue Fever - Pipeline by Biotron Ltd, H1 2020
- Dengue Fever - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
- Dengue Fever - Pipeline by Cidara Therapeutics Inc, H1 2020
- Dengue Fever - Pipeline by Clayton Biotechnologies Inc, H1 2020
- Dengue Fever - Pipeline by Codagenix Inc, H1 2020
- Dengue Fever - Pipeline by Emergex Vaccines Ltd, H1 2020
- Dengue Fever - Pipeline by Ennaid Therapeutics LLC, H1 2020
- Dengue Fever - Pipeline by Etna Biotech Srl, H1 2020
- Dengue Fever - Pipeline by Excivion Ltd, H1 2020
- Dengue Fever - Pipeline by Globavir Biosciences Inc, H1 2020
- Dengue Fever - Pipeline by Greffex Inc, H1 2020
- Dengue Fever - Pipeline by HSRx Group, H1 2020
- Dengue Fever - Pipeline by Humabs BioMed SA, H1 2020
- Dengue Fever - Pipeline by Immunomodulation Inc, H1 2020
- Dengue Fever - Pipeline by Immunotope Inc, H1 2020
- Dengue Fever - Pipeline by Imutex Ltd, H1 2020
- Dengue Fever - Pipeline by Indian Immunologicals Ltd, H1 2020
- Dengue Fever - Pipeline by Inovio Pharmaceuticals Inc, H1 2020
- Dengue Fever - Pipeline by Integral Molecular Inc, H1 2020
- Dengue Fever - Pipeline by ISLA Pharmaceuticals Inc, H1 2020
- Dengue Fever - Pipeline by Johnson & Johnson, H1 2020
- Dengue Fever - Pipeline by KM Biologics Co Ltd, H1 2020
- Dengue Fever - Pipeline by Macrophage Therapeutics Inc, H1 2020
- Dengue Fever - Pipeline by Medigen Inc, H1 2020
- Dengue Fever - Pipeline by Najit Technologies Inc, H1 2020
- Dengue Fever - Pipeline by Orgenesis Inc, H1 2020
- Dengue Fever - Pipeline by Panacea Biotec Ltd, H1 2020
- Dengue Fever - Pipeline by Plex Pharmaceuticals Inc, H1 2020
- Dengue Fever - Pipeline by ProtInhi BV, H1 2020
- Dengue Fever - Pipeline by Riboscience LLC, H1 2020
- Dengue Fever - Pipeline by Seagull Labs (I) Pvt Ltd, H1 2020
- Dengue Fever - Pipeline by Serum Institute of India Ltd, H1 2020
- Dengue Fever - Pipeline by Shionogi & Co Ltd, H1 2020
- Dengue Fever - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2020
- Dengue Fever - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
- Dengue Fever - Pipeline by TechnoVax Inc, H1 2020
- Dengue Fever - Pipeline by Virocovax, H1 2020
- Dengue Fever - Pipeline by Visterra Inc, H1 2020
- Dengue Fever - Pipeline by VLP Therapeutics LLC, H1 2020
- Dengue Fever - Pipeline by Xenothera SAS, H1 2020
- Dengue Fever - Dormant Projects, H1 2020
- Dengue Fever - Dormant Projects, H1 2020 (Contd..1), H1 2020
- Dengue Fever - Dormant Projects, H1 2020 (Contd..2), H1 2020
- Dengue Fever - Dormant Projects, H1 2020 (Contd..3), H1 2020
- Dengue Fever - Dormant Projects, H1 2020 (Contd..4), H1 2020
- Dengue Fever - Dormant Projects, H1 2020 (Contd..5), H1 2020
- Dengue Fever - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Dengue Fever, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 60 Degrees Pharmaceuticals LLC
- Abhelix LLC
- Abivax SA
- AbViro LLC
- Aluda Pharmaceuticals Inc
- Atea Pharmaceuticals Inc
- Avida Biotech SL
- Biological Mimetics Inc
- BioNet- Asia Co Ltd
- Biotron Ltd
- Chugai Pharmaceutical Co Ltd
- Cidara Therapeutics Inc
- Clayton Biotechnologies Inc
- Codagenix Inc
- Emergex Vaccines Ltd
- Ennaid Therapeutics LLC
- Etna Biotech Srl
- Excivion Ltd
- Globavir Biosciences Inc
- Greffex Inc
- HSRx Group
- Humabs BioMed SA
- Immunomodulation Inc
- Immunotope Inc
- Imutex Ltd
- Indian Immunologicals Ltd
- Inovio Pharmaceuticals Inc
- Integral Molecular Inc
- ISLA Pharmaceuticals Inc
- Johnson & Johnson
- KM Biologics Co Ltd
- Macrophage Therapeutics Inc
- Medigen Inc
- Najit Technologies Inc
- Orgenesis Inc
- Panacea Biotec Ltd
- Plex Pharmaceuticals Inc
- ProtInhi BV
- Riboscience LLC
- Seagull Labs (I) Pvt Ltd
- Serum Institute of India Ltd
- Shionogi & Co Ltd
- Sun Pharma Advanced Research Company Ltd
- Takeda Pharmaceutical Co Ltd
- TechnoVax Inc
- Virocovax
- Visterra Inc
- VLP Therapeutics LLC
- Xenothera SAS
